Compare IDEXX Laboratories, Inc. (IDXX) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $92.72 (market cap $5.86B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.9× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 7,780,002). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and State Street SPDR Bloomberg High Yield Bond ETF for 61 Days on average.
| IDXX | JNK | |
|---|---|---|
Market Cap | $40.43B | $5.86B |
Volume | 692,164 | 7,780,002 |
Sector | Health | Fixed Income |
52-Week High | $766.68 | $98.02 |
52-Week Low | $504.70 | $92.30 |
Typical Hold Time | 46 Days | 61 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
JNK (SPDR Bloomberg High Yield Bond ETF) trades at $92.81 with minimal daily movement (+0.05%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains consistent dividend payments of $0.53 per share. Recent news highlights institutional interest with Envestnet Asset Management increasing its stake by 23.3% during the latest quarter.
The outlook for JNK is challenged by rising bond yields and macroeconomic uncertainty. While consistent dividends provide income appeal, the bearish technical setup and high-yield bond sensitivity to interest rate hikes present near-term risks. Institutional accumulation suggests long-term confidence, but investors should monitor credit market conditions closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
